We are honoured to share this moving documentary "Dancing at the Vatican", an inspirational story of a seemingly impossible, cross-continental journey made by extraordinarily brave families bound by the same devastating disease, Huntington's, to bring their illness out of the shadows. The documentary brings to life IXICO's mission to advance medicine and human health by supporting innovations in clinical trials to accelerate bringing treatments to patients suffering from neurological disorders.
Given the uncertainties resulting from the ongoing COVID-19 pandemic, we have decided to move the 16th Annual HD Therapeutics Conference to a fully online, virtual experience. As in the past we will have scientific presentations, interactive poster sessions, and more – stay tuned for further details in the coming months.
This webinar will look at clinical and imaging biomarkers in Parkinsonian syndromes to provide trial sponsors a rounded overview of key challenges and considerations.
What You Will Learn:
- A clinical overview of parkinsonian syndromes with a focus on Parkinson’s disease (PD), multiple systems atrophy (MSA) and progressive supranuclear palsy (PSP)
- Addressing diagnostic challenges when recruiting for clinical trials
- Overview of the use of current imaging biomarkers in clinical trials in Parkinson’s disease
- Introduction to emerging imaging biomarkers in Parkinson’s disease
Join in-person or virtually for AAIC 2021, where the world’s leading basic scientists, clinical researchers, early career investigators, clinicians and the care research community will share breaking research discoveries that will lead to methods of prevention and treatment and improvements in diagnosis for Alzheimer’s disease.
The AD/PD series of Alzheimer’s and Parkinson’s Diseases Conferences is focused on unraveling the mechanisms and improving the treatment of Alzheimer’s, Parkinson’s and other related neurodegenerative diseases. AD/PD Conferences combine distinct neurodegenerative diseases in one setting and examine their similarities and differences; a strong focus is mechanisms of disease, prevention and therapy.
At the conference, IXICO will be making following presentations:
• Michael Reinwald, PhD, will give a pre-recorded oral presentation, titled: “A deep-learning based framework for brain-atrophy measurement”
• Jack Weatheritt, PhD, will present the poster: “Automatic segmentation using deep learning for the hippocampus”
• Luis Peraza, PhD, will present two posters:
1) “An adaptive step detection algorithm for waist-worn wearable devices: a feasibility study in older adults”
2) “Added value of wearable sensors for fall risk assessment in an older adult group”
Phase III clinical trials are required to prove the effectiveness and safety of a drug in a larger population. After decades of research, Alzheimer’s disease still has no disease-modifying drug that is approved as many of the drug development programs fail in later-stage phases. Due to the complexity of the disease and challenges associated with large scale later phase studies, Phase III Alzheimer’s clinical trials require neuroimaging approaches that successfully blend robust operational infrastructure, effective data management platform and advanced analytics.
This webinar will address practices to optimize the entire operational lifecycle including site qualification, investigator training and radiological reads in Alzheimer’s clinical trials.
In view of the large and complex data sets within Phase III trials, this webinar will present the advanced TrialTracker platform for scaling-up processes and systems to manage imaging data, from radiological read workflow to imaging analysis. It will additionally cover the AI-driven LEAP platform used to perform advanced segmentation and volumetric analysis in Alzheimer’s trials.
- Roger Bullock, Chief Medical Officer, Oryzon
- Shona Clegg, Senior Project Manager/Portfolio Lead, IXICO
- Richard Joules, Imaging Science Manager, IXICO
The development of the next generation of Alzheimer’s disease treatments is among the most important health needs worldwide, but presents huge challenges. The goal of the meeting is to bring together today’s worldwide leaders in the treatment of Alzheimer’s disease to discuss new results, candidate therapeutics, and methodological issues important to the development of the next generation of Alzheimer’s disease treatments. Clinical trial teams from worldwide centers will report on their efforts to identify new biomarkers of disease as well as more sensitive clinical assessment tools to identify those at risk for AD, to predict progression, and assess the effectiveness of new treatments. The future of clinical trials may lie in revisiting all drugs known to be safe and evaluate their relevance in AD treatment. We learned at CTAD 2019 of the importance of non-pharmaceutical trials and that anti-amyloid treatment for AD should begin early on in the disease process. We also discovered new promising treatments and we learned more of another pathway with Tau Biomarkers, and their implications for AD along with combination therapeutics and phase 3 clinical trials results. Again in 2020 Clinical teams will present their population studies on subjects in the early stage of the disease or even at the asymptomatic stage. CTAD 2020 will highlight the latest on trying to get these trials off the ground.